Here's How Much You'd Have If You Invested $1000 in Insulet a Decade Ago

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.

Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing stocks.

What if you'd invested in Insulet (PODD) ten years ago? It may not have been easy to hold on to PODD for all that time, but if you did, how much would your investment be worth today?

Insulet's Business In-Depth

With that in mind, let's take a look at Insulet's main business drivers.

Acton, MA-based Insulet Corporation manufactures and sells its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The company designed Omnipod, a small, lightweight, self-adhesive disposable tubeless device that can be worn in multiple locations, including the abdomen, hip, back of the upper arm, upper thigh or lower back.

The Omnipod platform consists of the following: the Omnipod 5 Insulin Management System (“Omnipod 5”), the Omnipod DASH Insulin Management System (“Omnipod DASH”) and the Omnipod Insulin Management System (“Classic Omnipod”).

In 2026, Insulet launched Omnipod Discover, a data analytics and reporting platform designed to give users, their caregivers and health care providers actionable insights.

The Omnipod products are currently available in 25 countries, including Belgium, Finland and Kuwait. For the year ended Dec. 31, 2025, 86% of Omnipod product sales globally were through intermediaries.

Insulet’s non-insulin Drug Delivery product line involves the development, manufacture and sale of a modified Pod for the delivery of a specific drug other than insulin. Substantially all of the company’s commercialized Drug Delivery revenues consist of sales of Pods to Amgen for use in the Neulasta Onpro kit, an innovative delivery system for Amgen’s white blood cell booster to help reduce the risk of infection after intense chemotherapy. The sales agreement expires in December 2028. Drug Delivery revenues were $34.1 million in 2025, down 12.3% from the 2024 figure.
 

Bottom Line

While anyone can invest, building a lucrative investment portfolio takes research, patience, and a little bit of risk. If you had invested in Insulet ten years ago, you're probably feeling pretty good about your investment today.

According to our calculations, a $1000 investment made in July 2016 would be worth $5,022.73, or a gain of 402.27%, as of July 13, 2026, and this return excludes dividends but includes price increases.

The S&P 500 rose 255.67% and the price of gold increased 193.80% over the same time frame in comparison.

Going forward, analysts are expecting more upside for PODD.

Insulet entered 2026 with strong momentum for Omnipod 5 in the Type 1 and early Type 2 diabetes markets, supported by its recurring pod model and broad pharmacy access. First-quarter results exceeded prior expectations, and management raised full-year revenue growth guidance while maintaining its margin expansion plan. Near-term drivers include the broader rollout of Omnipod 5 algorithm enhancements, including a 100 mg/dL target option and Libre 3 Plus integration, along with continued international expansion. Risks include costs and execution demands tied to the recent voluntary device correction, potential gross-margin pressure from product transitions and higher input and shipping costs, as well as intensifying competition and reimbursement scrutiny.

Shares have gained 7.74% over the past four weeks and there have been 1 higher earnings estimate revisions for fiscal 2026 compared to none lower. The consensus estimate has moved up as well.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research